Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Go or no go? Lilly’s valuable diabetes contender
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Corporate and regulatory developments over the Christmas period
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
